Two wrongs can make a right: Dimers of prolactin and growth hormone receptor antagonists behave as agonists

Molecular Endocrinology

Volumn 20, Issue 3, 2006, Pages 661-674

  Langenheim, John F ^a,b   Tan, Dunyong ^c   Walker, Ameae M ^c   Chen, Wen Y ^a,b  

^a CLEMSON UNIVERSITY   (United States)

^b GREENVILLE HOSPITAL SYSTEM   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HORMONE ANTAGONIST; HUMAN GROWTH HORMONE; HUMAN GROWTH HORMONE G120R; HUMAN PROLACTIN G129R; JANUS KINASE 2; MITOGEN ACTIVATED PROTEIN KINASE; PROLACTIN; PROLACTIN RECEPTOR; RAF PROTEIN; RAS PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; BINDING SITE; CELL PROLIFERATION; DIMERIZATION; EMBRYO; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; BINDING SITES; CARRIER PROTEINS; CELL PROLIFERATION; CELLS, CULTURED; DIMERIZATION; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMAN GROWTH HORMONE; HUMANS; LUMINESCENT MEASUREMENTS; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; PROLACTIN; PROTO-ONCOGENE PROTEINS C-AKT; RATS; RECEPTORS, PROLACTIN; RECOMBINANT FUSION PROTEINS; SIGNAL TRANSDUCTION; STAT5 TRANSCRIPTION FACTOR;

EID: 33344469275     PISSN: 08888809     EISSN: None     Source Type: Journal    
DOI: 10.1210/me.2005-0360     Document Type: Article

References (61)

1. de Vos AM, Ultsch M, Kossiakoff AA 1992 Human growth hormone and extracellular domain of its receptor: crystal structure of the complex. Science 255:306-312
2. Keeler C, Dannies PS, Hodsdon ME 2003 The tertiary structure and backbone dynamics of human prolactin. J Mol Biol 328:1105-1121
3. Forsyth IA, Wallis M 2002 Growth hormone and prolactin - molecular and functional evolution. J Mammary Gland Biol Neoplasia 7:291-312
4. Cunningham BC, Ultsch M, De Vos AM, Mulkerrin MG, Clauser KR, Wells JA 1991 Dimerization of the extracellular domain of the human growth hormone receptor by a single hormone molecule. Science 254:821-825
5. Ultsch M, de Vos AM, Kossiakoff AA 1991 Crystals of the complex between human growth hormone and the extracellular domain of its receptor. J Mol Biol 222:865-868
6. Fuh G, Colosi P, Wood WI, Wells JA 1993 Mechanism-based design of prolactin receptor antagonists. J Biol Chem 268:5376-5381
7. Goffin V, Struman I, Mainfroid V, Kinet S, Martial JA 1994 Evidence for a second receptor binding site on human prolactin. J Biol Chem 269:32598-32606
8. Fuh G, Wells JA 1995 Prolactin receptor antagonists that inhibit the growth of breast cancer cell lines. J Biol Chem 270:13133-13137
9. Sivaprasad U, Canfield JM, Brooks CL 2004 Mechanism for ordered receptor binding by human prolactin. Biochemistry 43:13755-13765
10. Walsh ST, Sylvester JE, Kossiakoff AA 2004 The high- and low-affinity receptor binding sites of growth hormone are allosterically coupled. Proc Natl Acad Sci USA 101:17078-17083
11. Chen WY, White ME, Wagner TE, Kopchick JJ 1991 Functional antagonism between endogenous mouse growth hormone (GH) and a GH analog results in dwarf transgenic mice. Endocrinology 129:1402-1408
12. Chen WY, Chen NY, Yun J, Wagner TE, Kopchick JJ 1994 In vitro and in vivo studies of antagonistic effects of human growth hormone analogs. J Biol Chem 269:15892-15897
13. Goffin V, Kinet S, Ferrag F, Binart N, Martial JA, Kelly PA 1996 Antagonistic properties of human prolactin analogs that show paradoxical agonistic activity in the Nb2 bioassay. J Biol Chem 271:16573-16579
14. Chen WY, Ramamoorthy P, Chen N, Sticca R, Wagner TE 1999 A human prolactin antagonist, hPRL-G129R, inhibits breast cancer cell proliferation through induction of apoptosis. Clin Cancer Res 5:3583-3593
15. Sundstrom M, Lundqvist T, Rodin J, Giebel LB, Milligan D, Norstedt G 1996 Crystal structure of an antagonist mutant of human growth hormone, G120R, in complex with its receptor at 2.9 A resolution. J Biol Chem 271:32197-32203
16. Clackson T, Ultsch MH, Wells JA, de Vos AM 1998 Structural and functional analysis of the 1:1 growth hormone:receptor complex reveals the molecular basis for receptor affinity. J Mol Biol 277:1111-1128
17. Carter-Su C, Stubbart JR, Wang XY, Stred SE, Argetsinger LS, Shafer JA 1989 Phosphorylation of highly purified growth hormone receptors by a growth hormone receptor-associated tyrosine kinase. J Biol Chem 264:18654-18661
18. Rui H, Kirken RA, Farrar WL 1994 Activation of receptor-associated tyrosine kinase JAK2 by prolactin. J Biol Chem 269:5364-5368
19. Dusanter-Fourt I, Muller O, Ziemiecki A, Mayeux P, Drucker B, Djiane J, Wilks A, Harpur AG, Fischer S, Gisselbrecht S 1994 Identification of JAK protein tyrosine kinases as signaling molecules for prolactin. Functional analysis of prolactin receptor and prolactin-erythropoietin receptor chimera expressed in lymphoid cells. EMBO J 13:2583-2591
20. Lebrun JJ, Ali S, Sofer L, Ullrich A, Kelly PA 1994 Prolactin-induced proliferation of Nb2 cells involves tyrosine phosphorylation of the prolactin receptor and its associated tyrosine kinase JAK2. J Biol Chem 269:14021-14026
21. Campbell GS, Argetsinger LS, Ihle JN, Kelly PA, Rillema JA, Carter-Su C 1994 Activation of JAK2 tyrosine kinase by prolactin receptors in Nb2 cells and mouse mammary gland explants. Proc Natl Acad Sci USA 91:5232-5236
22. Das R, Vonderhaar BK 1996 Involvement of SHC, GRB2, SOS and RAS in prolactin signal transduction in mammary epithelial cells. Oncogene 13:1139-1145
23. Das R, Vonderhaar BK 1996 Activation of raf-1, MEK, and MAP kinase in prolactin responsive mammary cells. Breast Cancer Res Treat 40:141-149
24. Socolovsky M, Nam H, Fleming MD, Haase VH, Brugnara C, Lodish HF 2001 Ineffective erythropoiesis in Stat5a (-/-)5b(-/-) mice due to decreased survival of early erythroblasts. Blood 98:3261-3273
25. Shillingford JM, Miyoshi K, Robinson GW, Grimm SL, Rosen JM, Neubauer H, Pfeffer K, Hennighausen L 2002 Jak2 is an essential tyrosine kinase involved in pregnancy-mediated development of mammary secretory epithelium. Mol Endocrinol 16:563-570
26. Schneider AB, Kowalski K, Sherwood LM 1975 Identification of "big" human placental lactogen in placenta and serum. Endocrinology 97:1364-1372
27. Stolar MW, Amburn K, Baumann G 1984 Plasma "big" and "big-big" growth hormone (GH) in man: an oligomeric series composed of structurally diverse GH monomers. J Clin Endocrinol Metab 59:212-218
28. Smith CR, Norman MR 1990 Prolactin and growth hormone: molecular heterogeneity and measurement in serum. Ann Clin Biochem 27:542-550
29. Sinha YN 1995 Structural variants of prolactin: occurrence and physiological significance. Endocr Rev 16:354-369
30. Fahie-Wilson MN, John R, Ellis AR 2005 Macroprolactin; high molecular mass forms of circulating prolactin. Ann Clin Biochem 42:175-192
31. Brostedt P, Luthman M, Wide L, Werner S, Roos P 1990 Characterization of dimeric forms of human pituitary growth hormone by bioassay, radioreceptor assay, and radioimmunoassay. Acta Endocrinol (Copenh) 122:241-248
32. Baumann G 1991 Growth hormone heterogeneity: genes, isohormones, variants, and binding proteins. Endocr Rev 12:424-449
33. Schneider AB, Kowalski K, Buckman G, Sherwood LM 1977 Dimeric ("big") human placental lactogen. Immunological and biological activity. Biochim Biophys Acta 493:69-77
34. Djiane J, Dusanter-Fourt I, Katoh M, Kelly PA 1985 Biological activities of binding site specific monoclonal antibodies to prolactin receptors of rabbit mammary gland. J Biol Chem 260:11430-11435
35. Okamura H, Zachwieja J, Raguet S, Kelly PA 1989 Characterization and applications of monoclonal antibodies to the prolactin receptor. Endocrinology 124:2499-2508
36. Elberg G, Kelly PA, Djiane J, Binder L, GertlerA1990 Mitogenic and binding properties of monoclonal antibodies to the prolactin receptor in Nb2 rat lymphoma cells. Selective enhancement by anti-mouse IgG. J Biol Chem 265:14770-14776
37. Rui H, Lebrun JJ, Kirken RA, Kelly PA, Farrar WL 1994 JAK2 activation and cell proliferation induced by antibody-mediated prolactin receptor dimerization. Endocrinology 135:1299-1306
38. Cunningham BC, Wells JA 1989 High-resolution epitope mapping of hGH-receptor interactions by alanine-scanning mutagenesis. Science 244:1081-1085
39. Cunningham BC, Wells JA 1991 Rational design of receptor-specific variants of human growth hormone. Proc Natl Acad Sci USA 88:3407-3411
40. Rozakis-Adcock M, Kelly PA 1992 Identification of ligand binding determinants of the prolactin receptor. J Biol Chem 267:7428-7433
41. Cunningham BC, Bass S, Fuh G, Wells JA 1990 Zinc mediation of the binding of human growth hormone to the human prolactin receptor. Science 250:1709-1712
42. Kossiakoff AA, Somers W, Ultsch M, Andow K, Muller YA, De Vos AM 1994 Comparison of the intermediate complexes of human growth hormone bound to the human growth hormone and prolactin receptors. Protein Sci 3:1697-1705
43. Cunningham BC, Jhurani P, Ng P, Wells JA 1989 Receptor and antibody epitopes in human growth hormone identified by homolog-scanning mutagenesis. Science 243:1330-1336
44. Goffin V, Norman M, Martial JA 1992 Alanine-scanning mutagenesis of human prolactin: importance of the 58-74 region for bioactivity. Mol Endocrinol 6:1381-1392
45. Ultsch MH, Somers W, Kossiakoff AA, de Vos AM 1994 The crystal structure of affinity-matured human growth hormone at 2 A resolution. J Mol Biol 236:286-299
46. Cunningham BC, Henner DJ, Wells JA 1990 Engineering human prolactin to bind to the human growth hormone receptor. Science 247:1461-1465
47. Schneider AB, Kowalski K, Sherwood LM 1975 "Big" human placental lactogen: disulfide-linked peptide chains. Biochem Biophys Res Commun 64:717-724
48. Grigorian AL, Bustamante JJ, Hernandez P, Martinez AO, Haro LS 2005 Extraordinarily stable disulfide-linked homodimer of human growth hormone. Protein Sci 14:902-913
49. Grigorian AL, Bustamante JJ, Aguilar RM, Martinez AO, Haro LS, 45 kDa Mercaptoethanol-resistant human growth hormone binds to somatogenic and lactogenic receptors. Program of the 84th Annual Meeting of The Endocrine Society, San Francisco, CA, 2002, p 555 (Abstract P3-273)
50. Grigorian AL, Bustamante JJ, Aguilar RM, Muñoz J, Martinez AO, Haro LS, Characterization of 45 kDa mercaptoethanol-resistant human growth hormone by radioimmunoassay and bioassays. Program of the 85th Annual Meeting of The Endocrine Society, Philadelphia, PA, 2003, p 381 (Abstract P2-313)
51. Muñoz J, Esquivel J, Bustamante JJ, Martinez AO, Haro LS, Anti-proliferative effects of a 2-mercaptoethanol resistant 45 kDa human growth hormone variant in MCF-7, MDA-MB-231 and T47D human breast cancer cell lines. Program of the 86th Annual Meeting of The Endocrine Society, New Orleans, LA, 2004, p 375 (Abstract P2-228)
52. Muñoz J, Aguilar RM, Vargas M, Martinez AO, Haro LS, β-Mercaptoethanol resistant 45-kDa human growth hormone inhibits STAT activation in T47-D, MCF-7 and MDA-MB-231 human breast cancer cell lines. Program of the 87th Annual Meeting of The Endocrine Society, San Diego, CA, 2005, p 563 (Abstract P114-5)
53. Tan D, Johnson DA, Wu W, Zeng L, Chen YH, Chen WY, Vonderhaar BK, Walker AM 2005 Unmodified prolactin (PRL) and S179D PRL-initiated bioluminescence resonance energy transfer between homo- and hetero-pairs of long and short human prolactin receptors in living human cells. Mol Endocrinol 19:1291-1303
54. Tsunekawa B, Wada M, Ikeda M, Uchida H, Naito N, Honjo M 1999 The 20-kilodalton (kDa) human growth hormone (hGH) differs from the 22-kDa hGH in the effect on the human prolactin receptor. Endocrinology 140:3909-3918
55. Somers W, Ultsch M, De Vos AM, Kossiakoff AA 1994 The X-ray structure of a growth hormone-prolactin receptor complex. Nature 372:478-481
56. Qiu H, Belanger A, Yoon HW, Bunn HF 1998 Homodimerization restores biological activity to an inactive erythropoietin mutant. J Biol Chem 273:11173-11176
57. Sytkowski AJ, Lunn ED, Risinger MA, Davis KL 1999 An erythropoietin fusion protein comprised of identical repeating domains exhibits enhanced biological properties. J Biol Chem 274:24773-24778
58. Dalle B, Henri A, Rouyer-Fessard P, Bettan M, Scherman D, Beuzard Y, Payen E 2001 Dimeric erythropoietin fusion protein with enhanced erythropoietic activity in vitro and in vivo. Blood 97:3776-3782
59. Zhang G, Li W, Holle L, Chen N, Chen WY 2002 A novel design of targeted endocrine and cytokine therapy for breast cancer. Clin Cancer Res 8:1196-1205
60. Beck MT, Chen NY, Franek KJ, Chen WY 2003 Prolactin antagonist-endostatin fusion protein as a targeted dual-functional therapeutic agent for breast cancer. Cancer Res 63:3598-3604
61. Langenheim JF, Chen WY 2005 Development of a prolactin receptor-targeting fusion toxin using a prolactin antagonist and a recombinant form of Pseudomonas exotoxin A. Breast Cancer Res Treat 90:281-293